Dr. Jeffrey A. Meyerhardt
Claim this profileDana-Farber Cancer Institute
Studies Colorectal Cancer
Studies Rectal Cancer
8 reported clinical trials
18 drugs studied
Area of expertise
1Colorectal Cancer
Stage III
Stage IV
Stage II
2Rectal Cancer
Stage II
Stage III
MSH2 negative
Affiliated Hospitals
Clinical Trials Jeffrey A. Meyerhardt is currently running
Chemotherapy + Bevacizumab + Atezolizumab
for Colorectal Cancer
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Recruiting2 awards Phase 31 criteria
Prehabilitation Program
for Rectal Cancer
The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection. The names of the groups in this research study are: * Group A: Prehabilitation program * Group B: Usual Care
Recruiting1 award N/A2 criteria
More about Jeffrey A. Meyerhardt
Clinical Trial Related7 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jeffrey A. Meyerhardt has experience with
- Radiation Therapy
- Atezolizumab
- Oxaliplatin
- Aerobic Exercise
- Progressive Stretching
- Prehabilitation Program
Breakdown of trials Jeffrey A. Meyerhardt has run
Colorectal Cancer
Rectal Cancer
Skin Cancer
Biliary Tract Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey A. Meyerhardt specialize in?
Jeffrey A. Meyerhardt focuses on Colorectal Cancer and Rectal Cancer. In particular, much of their work with Colorectal Cancer has involved Stage III patients, or patients who are Stage IV.
Is Jeffrey A. Meyerhardt currently recruiting for clinical trials?
Yes, Jeffrey A. Meyerhardt is currently recruiting for 5 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey A. Meyerhardt has studied deeply?
Yes, Jeffrey A. Meyerhardt has studied treatments such as Radiation Therapy, Atezolizumab, Oxaliplatin.
What is the best way to schedule an appointment with Jeffrey A. Meyerhardt?
Apply for one of the trials that Jeffrey A. Meyerhardt is conducting.
What is the office address of Jeffrey A. Meyerhardt?
The office of Jeffrey A. Meyerhardt is located at: Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana-Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.